Relief of symptoms associated with allergic rhinitis and urticaria.
Composition:
1 tabl powl. contains 5 mg desloratadine. The tablets contain lactose. 1 ml oral solution contains 0.5 mg desloratadine. The solution contains sorbitol.
Action:
Desloratadine is a sedative, long-acting histamine antagonist with selective antagonistic activity towards peripheral H-receptors1. It does not penetrate to o.u.n. Antiallergic properties of desloratadine include inhibiting the release of cytokines inducing an inflammatory response (i.e., IL-4, IL-6, IL-8 and IL-13) from human mast cells and basophils, as well as inhibiting the expression of P-selectin on the surface of endothelial cells. In patients with allergic rhinitis, desloratadine effectively relieves symptoms such as sneezing, itching and discharge from the nose, tearing and redness of the eyes and itching of the palate, while in patients with urticaria, it reduces the number and size of urticaria changes and soothes pruritus. Desloratadine is rapidly absorbed from the gastrointestinal tract (approximately 30 min), reaching Cmax in the blood after about 3 h. Plasma protein binding is 83-87%. T0,5 in the blood is 27 hours.
Contraindications:
Hypersensitivity to the active substance, to any of the excipients or to loratadine.
Precautions:
Use caution in severe renal failure. Due to the lactose content, tablets should not be used in patients with galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose. The oral solution contains sorbitol - it should not be used in patients with fructose intolerance, impaired glucose-galactose absorption or sucrose isomaltase deficiency; The safety and efficacy of oral solution in infants up to 1 year of age and tablets in children under 12 years have not been established. There are insufficient data on the efficacy of tablets and oral solution in children and adolescents from 1 to 17 years of age.
Pregnancy and lactation:
The safety of the medicine during pregnancy has not been established. It is recommended to avoid the use of the preparation during pregnancy. Desloratadine is excreted in breast milk. A decision should be made whether to discontinue breast-feeding or discontinue the preparation, taking into account the benefits of breastfeeding for the child and the benefits of treatment for the mother.
Side effects:
Fatigue, dryness of the oral mucosa and headache were most commonly observed; and in children from 6 to 23 months: diarrhea, fever and insomnia. Very rare: hallucinations, dizziness, drowsiness, insomnia, psychomotor agitation, convulsions, tachycardia, palpitations, abdominal pain, nausea, vomiting, indigestion, diarrhea, increased liver enzymes, increased bilirubin in the blood, hepatitis, muscle pain, hypersensitivity reactions (including anaphylaxis, angioneurotic edema, dyspnoea, pruritus, rash, urticaria).
Dosage:
Orally. Adults and adolescents from 12 years: 5 mg once a day (1 table of 5 mg or 10 ml of oral solution, children from 1 to 5 years of age: 1.25 mg (2.5 ml of oral solution) once a day; 6-11 years: 2.5 mg (5 ml oral solution) once a day The product can be taken regardless of meals The treatment should be discontinued after the symptoms have resolved and resumed once they occur again. In chronic allergic rhinitis you can continue treatment during the period of allergen exposure.
(C)
